Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADL5945 for Opioid-induced Constipation
NCT01207427Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2010
- Primary completion
- Apr 2011
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of bevenopran in opioid-induced constipation (OIC) (3 arms), sponsored by Merck & Co. Primary endpoint: Change From Baseline in the Weekly Average of Spontaneous Bowel Movements (SBMs) During Treatment at 4 weeks. Started Oct 2010; status: completed.
02
Drugs
bevenopran
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT01207427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01207427.